Barclays Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $260
Barclays Reaffirms Their Buy Rating on Veeva Systems (VEEV)
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Veeva Systems (VEEV) and Takeda Pharmaceutical Company (TAK)
Veeva Systems Analyst Ratings
William Blair Maintains Veeva Systems(VEEV.US) With Buy Rating
Veeva Systems: Strong Market Position and Future Growth Potential Drive Buy Rating
BTIG Remains a Buy on Veeva Systems (VEEV)
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Veeva Systems (VEEV) and Neuren Pharmaceuticals Limited (OtherNURPF)
A Quick Look at Today's Ratings for Veeva Systems(VEEV.US), With a Forecast Between $230 to $280
Veeva Systems Analyst Ratings
Veeva Systems Is Maintained at Outperform by RBC Capital
A Quick Look at Today's Ratings for Veeva Systems(VEEV.US), With a Forecast Between $260 to $280
Veeva Systems (VEEV) Receives a Buy From Barclays
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Veeva Systems (VEEV)
Veeva Systems Is Maintained at Overweight by Piper Sandler
Veeva Systems Analyst Ratings
Truist Financial Maintains Veeva Systems(VEEV.US) With Hold Rating
Morgan Stanley Maintains Veeva Systems(VEEV.US) With Sell Rating, Maintains Target Price $173
Veeva Systems (VEEV) Receives a Hold From Truist Financial
Sell Rating for Veeva Systems Amid CRM Challenges and Strategic Concerns